Eton expands infantile hemangioma franchise with ASN-001 acquisition
Eton Pharmaceuticals licensed the late-stage ASN-001 drug from Auson Pharmaceuticals for treating infantile hemangiomas, projecting significant portfolio revenue growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day